Mölnlycke unveils new Mepilex® innovations at EWMA conference

Mölnlycke is set to launch updated Mepilex® Border Sacrum and Mepilex® Border Heel dressings, followed by new Mepilex® Border Flex and Mepilex® Border Post-Op dressings to be released later this year. 

Gothenburg, Sweden – 4 May 2017 

Mölnlycke, a world-leading medical products and solutions company, today unveiled innovations in its Mepilex ® product range at the 27th conference of the European Wound Management Association (EWMA) in Amsterdam, the Netherlands. Mepilex ® Border Sacrum and Mepilex ® Border Heel dressings for treatment and prevention of pressure ulcers now have enhanced user features that are optimised for easy handling.

New Mepilex ® Border Flex is an all-in-one foam dressing with next-generation Flex technology. It can be used to manage a wide range of exuding wounds. Mepilex ® Border Post-Op can improve patient comfort and reduce post-operative dressing-related costs through its longevity (note 1-2).

Both Mepilex ® Border Flex and Mepilex ® Border Post-Op have a flex-cut design that stretches in all directions, conforming to the body even as it moves (note 3).

Mölnlycke has a strong focus on product innovations and clinical outcomes. The company works with leading clinicians and wound care organisations around the world; together, building on best practice, and gathering evidence to demonstrate improvements in treatment and prevention. Mölnlycke wants to build on its strong heritage in product innovation, continuing to drive the future of wound care treatment and prevention.

Mölnlycke Chief Executive Officer Richard Twomey said: ‘For Mölnlycke, it’s all about the outcome. Our strong focus on product innovation and clinical evidence has continuously changed the way wounds are treated and prevented. This year at EWMA, we’re proud to unveil more innovations in our Mepilex® range. Now healthcare professionals have more solutions that deliver better patient and budget outcomes.’ 

References:

1. Zarghooni, K., Bredow, J., Siewe, J., Deutloff, N., Meyer, H.S., Lohmann C. Is the use of modern versus conventional wound dressings warranted after primary knee and hip arthroplasty? Acta Orthopaedica Belgica 2015;81(4):768-775.

2. Bredow, J., Hoffmann, K., Hellmich, M., Eysel, P., Zarghooni, K. Randomised clinical trial to evaluate performance of flexible self-adherent absorbent dressing coated with silicone layer after hip, knee or spinal surgery in comparison to standard wound dressing. Poster presentation at the 5th Congress of the World Union of Wound Healing Societies, Florence, Italy, 2016.

3. Van Overschelde, P., Beele, H., Ponzer, S. A randomised controlled trial com[paring two wound dressings used after elective hip and knee arthroplasty. Poster presentation at the 5th Congress of the World Uniof of Wound Healing Societies, Florence, Italy, 2016.

For further information, please contact:

Anna Bertilsson, Global Marketing Director, Chronic Wound Care

anna.bertilsson@molnlycke.com

+46739412914 

Notes for the editors:

Mölnlycke is a world-leading medical solutions company. We design and supply solutions t o enhance performance at every point of care – from the hospital to the home. We specialise in:

Wound management: including dressings with Safetac® such as Mepitel® and Mepilex® and Avance® for negative pressure wound therapy.

Preventing pressure ulcers: with Mepilex ® Border used prophylactically and  devices to help turn and re-position patients.

Surgical solutions: including Mölnlycke procedure trays, BARRIER ® surgical  drapes and staff clothing, Hibi® antiseptics and Biogel® surgical gloves.

Mölnlycke was founded in 1849. Nowadays our solutions are available in around 100  countries; we are the number one global provider of advanced wound care and single-use surgical products; and we are Europe's largest provider of customised trays. Our headquarters are in Gothenburg, Sweden and we have about 7,500 employees around the world. For more information, please visit www.molnlycke.com .

The Mölnlycke, Mepilex, Mepitel, BARRIER, Biogel, Hibi, Avance and Safetac trademarks, names and logotypes are registered globally to one or more of the Mölnlycke Health Care Group of Companies. © 2017 Mölnlycke Health Care AB. All rights reserved. 

Tags:

About Us

Mölnlycke is a world-leading medical solutions company. We design and supply solutions to enhance performance at every point of care – from the hospital to the home. We specialise in solutions for managing wounds, improving surgical safety and efficiency, and preventing pressure ulcers. Our products are available in approximately 100 countries worldwide. Mölnlycke was founded in 1849. Our headquarters are in Gothenburg, Sweden and we employ around 7,500 people. Since 2007, we belong to Investor AB, the leading owner of Nordic-based international companies.

Subscribe

Quotes

Our strong focus on product innovation and clinical evidence has continuously changed the way wounds are treated and prevented.
Richard Twomey, CEO